SCHEMBL21027975

SCHEMBL21027975

CS(=O)(=O)c1ccc(Cc2c3n(c4ccccc24)C(C(=O)O)CCC3)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 10/20 0.44
PTGDR Q13258 6/20 0.39
MAPK8 P45983 1/20 0.37
CCR2 P41597 2/20 0.37
KDM4E B2RXH2 2/20 0.37
MEN1 O00255 1/20 0.37
GLA P06280 1/20 0.37
CASP1 P29466 1/20 0.37
CASP7 P55210 1/20 0.37
KMT2A Q03164 1/20 0.37
HSD17B10 Q99714 1/20 0.37
ALOX5 P09917 1/20 0.36
TBXA2R P21731 3/20 0.36
CYP2C9 P11712 2/20 0.36
MAPT P10636 1/20 0.36
RXFP1 Q9HBX9 1/20 0.36
HTR6 P50406 1/20 0.36
CYP3A4 P08684 1/20 0.36
DRD2 P14416 1/20 0.36
GABRA1 P14867 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21028081 0.88 PTGDR2 (0.39) PTGDR2PTGDRMAPK8
SCHEMBL21028026 0.87 PTGDR2 (0.46) PTGDR2PTGDRMEN1KMT2AHSD17B10
SCHEMBL21028287 0.82 PTGDR2 (0.41) PTGDR2PTGDRTBXA2RCYP2C9CYP3A4
SCHEMBL21028023 0.82 PTGDR2 (0.39) PTGDR2PTGDRMAPK8KDM4E
SCHEMBL24141336 0.78 PER2 (0.39) PTGDR2PTGDRMAPK8CCR2
SCHEMBL21027972 0.75 PTGDR2 (0.45) PTGDR2PTGDRMEN1KMT2AHTR6
SCHEMBL21028288 0.74 PTGDR2 (0.52) PTGDR2PTGDRTBXA2RCYP2C9CYP3A4
SCHEMBL21028077 0.74 MEN1 (0.41) KDM4EMEN1GLACASP1CASP7
SCHEMBL21027976 0.74 PTGDR2 (0.49) PTGDR2PTGDRTBXA2RCYP2C9CYP3A4
SCHEMBL21027857 0.74 PTGDR2 (0.47) PTGDR2PTGDRKDM4ETBXA2RMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11524958-B2 Tricyclic compound as CRTH2 inhibitor CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) 2022-12-13 US disclosed
US-20210403466-A1 TRICYCLIC COMPUND AS CRTH2 INHIBITOR CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) 2021-12-30 US disclosed
EP-3489235-A1 TRICYCLIC COMPOUND AS CRTH2 INHIBITOR Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) 2019-05-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210403466-A1 TRICYCLIC COMPUND AS CRTH2 INHIBITOR NR3C2, CRHR2, CRHR1 PTGDR2 152/4885PTGDR 412/4885MAPK8 1300/4885
US-11524958-B2 Tricyclic compound as CRTH2 inhibitor NR1H2, NR3C2, NR1H4 PTGDR2 313/4885PTGDR 550/4885MAPK8 701/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.